Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8431 to 8445 of 8914 results

  1. Synergo for non-muscle-invasive bladder cancer (MIB226)

    This advice has been updated and replaced by NICE healthtech guidance 601.

  2. AnaConDa-S for sedation with volatile anaesthetics in intensive care (MIB229)

    This advice has been updated and replaced by NICE healthtech guidance 607.

  3. 3C Patch System for treating diabetic foot ulcers (MIB230)

    This advice has been updated and replaced by NICE Healthtech guidance 615.

  4. KardiaMobile for the ambulatory detection of atrial fibrillation (MIB232)

    This advice has been updated and replaced by NICE healthtech guidance 606.

  5. TheraSphere for treating operable and inoperable hepatocellular carcinoma (MIB62)

    This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.

  6. SIR-Spheres for treating inoperable hepatocellular carcinoma (MIB63)

    This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.

  7. VitalPAC for assessing vital signs of patients in hospital (MIB79)

    This advice has been updated and replaced by NICE medtech innovation briefing 205.

  8. UrgoStart for chronic wounds (MIB82)

    This advice has been updated and replaced by NICE medical technologies guidance 42.

  9. Absorb Bioresorbable Vascular Scaffold system for coronary artery disease (MIB84)

    NICE withdrew this medtech innovation briefing in November 2017 after the company stopped manufacturing Absorb because of low uptake. Some UK hospitals continue to use the technology in ongoing clinical studies.